https://www.businesswire.com/news/home/20190411005258/en/

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Apr 11, 2019--Castle Biosciences, Inc., a skin cancer diagnostics company providing personalized genomic information to improve cancer management decisions, today announced publication of an independent, prospective study of 159 patients with cutaneous melanoma showing that the DecisionDx ® -Melanoma gene expression profile (GEP) test accurately identified risk of melanoma recurrence independent of other prognostic factors such as Breslow thickness and sentinel lymph node biopsy (SLNB) result. The study was published in the journal Cancer Medicine and is consistent with previously published prospective and retrospective studies demonstrating the high performance of DecisionDx-Melanoma to predict outcomes, supporting its clinical value to inform patient management decisions.

“In this prospective study with 3.5 years of overall follow up, DecisionDx-Melanoma was shown to be an independent prognostic factor that is additive to traditional staging factors,” commented lead study investigator Eddy C. Hsueh, M.D., Professor and Director, Division of General Surgery, St. Louis University Hospital. “Accurate risk assessment for cutaneous melanoma is increasingly important to inform patient management decisions including surveillance, follow-up and potential adjuvant therapy consideration.”